Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.
Sarah Cannon Research Institute, Nashville, TN, USA.
Invest New Drugs. 2018 Oct;36(5):869-876. doi: 10.1007/s10637-018-0570-4. Epub 2018 Feb 17.
Background CD37 is expressed on B-cell lymphoid malignancies, thus making it an attractive candidate for targeted therapy in non-Hodgkin lymphoma (NHL). IMGN529 is an antibody-drug conjugate comprising a CD37-binding antibody linked to the maytansinoid DM1, a potent anti-mitotic agent. Methods This first-in-human, phase 1 trial recruited adult patients with relapsed or refractory B-cell NHL. The primary objective was to determine the maximum tolerated dose (MTD) and recommended phase 2 dose. Secondary objectives were to evaluate safety, pharmacokinetics, and preliminary clinical activity. IMGN529 was administered intravenously once every 3 weeks, and dosed using a conventional 3 + 3 dose-escalation design. Results Forty-nine patients were treated at doses escalating from 0.1 to 1.8 mg/kg. Dose limiting toxicities occurred in eight patients and included peripheral neuropathy, febrile neutropenia, neutropenia, and thrombocytopenia. The most frequent treatment-emergent adverse events were fatigue (39%), neutropenia, pyrexia, and thrombocytopenia (each 37%). Adverse events led to treatment discontinuation in 10 patients (20%). Eight patients (16%) had treatment-related serious adverse events, the most common being grade 3 febrile neutropenia. The MTD (with growth factor support) was 1.4 mg/kg every 3 weeks. IMGN529 plasma exposure increased monotonically with dose and was consistent with target-mediated drug disposition. Five (13%) of 39 response-evaluable patients achieved an objective response (one complete response and four partial responses), four of which occurred in the subgroup of patients with diffuse large B-cell lymphoma. Conclusions The manageable safety profile of IMGN529 and preliminary evidence of activity, particularly in DLBCL patients, support the continued development of this novel CD37-targeting agent.
CD37 在 B 细胞淋巴瘤中表达,因此成为非霍奇金淋巴瘤(NHL)靶向治疗的有吸引力的候选药物。IMGN529 是一种抗体药物偶联物,由与美坦新素 DM1 连接的 CD37 结合抗体组成,DM1 是一种有效的抗有丝分裂剂。
这项首次在人体中进行的 1 期试验招募了复发或难治性 B 细胞 NHL 的成年患者。主要目的是确定最大耐受剂量(MTD)和推荐的 2 期剂量。次要目标是评估安全性、药代动力学和初步临床活性。IMGN529 每 3 周静脉注射一次,采用传统的 3+3 剂量递增设计进行给药。
49 名患者接受了 0.1 至 1.8mg/kg 剂量递增的治疗。8 名患者出现剂量限制毒性,包括周围神经病、发热性中性粒细胞减少症、中性粒细胞减少症和血小板减少症。最常见的治疗后出现的不良事件是疲劳(39%)、中性粒细胞减少症、发热和血小板减少症(各 37%)。10 名患者(20%)因不良事件而停止治疗。8 名患者(16%)发生了与治疗相关的严重不良事件,最常见的是 3 级发热性中性粒细胞减少症。(在生长因子支持下)MTD 为每 3 周 1.4mg/kg。IMGN529 血浆暴露量随剂量单调增加,与靶介导的药物处置一致。39 名可评估反应的患者中有 5 名(13%)达到客观缓解(1 例完全缓解和 4 例部分缓解),其中 4 例发生在弥漫性大 B 细胞淋巴瘤患者亚组中。
IMGN529 的安全性特征可控,且初步的活性证据,特别是在 DLBCL 患者中,支持继续开发这种新型 CD37 靶向药物。